Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

View/ Open
Issue date
2015Author
Garcia-Alfonso, Pilar
Chaves, Manuel
Muñoz, Andrés
García-Gonzalez, Maria
Grávalos, Cristina
Massuti, Bartomeu
González-Flores, Encarna
Queralt, Bernardo
López-Ladrón, Amelia
Losa, F.
Gómez, Maria Jose
Oltra, Amparo
Aranda, Enrique
Suggested citation
Garcia-Alfonso, Pilar;
Chaves, Manuel;
Muñoz, Andrés;
Salud Salvia, Maria Antonieta;
García-Gonzalez, Maria;
Grávalos, Cristina;
...
Aranda, Enrique.
(2015)
.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
BMC Cancer, 2015, vol.15, núm. 327.
https://doi.org/10.1186/s12885-015-1293-y.
Metadata
Show full item recordAbstract
Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic
colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard
capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC.
Methods: Patients received intravenous irinotecan 175 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 (800 mg/m2
for patients >65 years of age) twice daily on days 2–8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an
intravenous infusion on day 1 every 2 weeks.
Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival
at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median
progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one
grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over
the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1–11.
Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with
mCRC to be an effective and tolerable regimen.
Trial registration: clinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009.
Keywords: Irinotecan, Capecitabine, Bevacizumab, Metastatic colorectal cancer, Chemotherapy
Is part of
BMC Cancer, 2015, vol.15, núm. 327European research projects
Collections
The following license files are associated with this item: